NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $7.64 -0.55 (-6.72%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$7.64 0.00 (-0.07%) As of 08/25/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cullinan Therapeutics Stock (NASDAQ:CGEM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$7.54▼$8.1550-Day Range$7.03▼$8.3452-Week Range$6.85▼$19.89Volume220,874 shsAverage Volume381,468 shsMarket Capitalization$451.29 millionP/E RatioN/ADividend YieldN/APrice Target$26.80Consensus RatingBuy Company Overview Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCGEM MarketRank™: Cullinan Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 695th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCullinan Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.83% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.83% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.86 News SentimentCullinan Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Cullinan Therapeutics this week, compared to 3 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.07% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Stock News HeadlinesCullinan Therapeutics to Participate in Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comCullinan Therapeutics assumed with a Buy at H.C. WainwrightAugust 21, 2025 | msn.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained. | American Alternative (Ad)Morgan Stanley Issues Pessimistic Forecast for Cullinan Therapeutics (NASDAQ:CGEM) Stock PriceAugust 19, 2025 | americanbankingnews.comCullinan Therapeutics: Q2 Earnings SnapshotAugust 7, 2025 | finance.yahoo.comCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comCullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung CancerAugust 1, 2025 | msn.comCullinan Therapeutics: Betting On Zipalertinib NDA CatalystJuly 15, 2025 | seekingalpha.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $12.18 at the beginning of the year. Since then, CGEM stock has decreased by 37.3% and is now trading at $7.64. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.24. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' top institutional shareholders include Franklin Resources Inc. (3.77%), Geode Capital Management LLC (2.17%), Patient Square Capital LP (1.47%) and Bank of America Corp DE (1.12%). Insiders that own company stock include Nadim Ahmed, Jeffrey Alan Jones, Corrine Savill, Jennifer Michaelson and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/07/2025Today8/25/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Cullinan Therapeutics$26.80 High Price Target$36.00 Low Price Target$22.00 Potential Upside/Downside+250.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.56% Return on Assets-34.82% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.14 per share Price / Book0.75Miscellaneous Outstanding Shares59,070,000Free Float55,488,000Market Cap$451.29 million OptionableOptionable Beta-0.08 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CGEM) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredBreaking News: Trump Could Unlock $21 Trillion for Everyday AmericansPresident Trump just signed a new law… That could unlock $21 trillion for everyday folks like you… And p...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.